Scott Struthers
Founder at CRINETICS PHARMACEUTICALS, INC.
Net worth: 54 M $ as of 2024-03-30
Profile
Scott R.
Struthers is the founder.
He founded ScienceMedia, Inc. in 1995.
He also founded Crinetics Pharmaceuticals, Inc. in 2008, where he holds the title of President, Chief Executive Officer & Director.
In 2009, he founded The San Diego Entrepreneurs Exchange and serves as a Director.
In 2021, he founded Radionetics Oncology, Inc. and currently serves as Chairman.
Dr. Struthers also held a former job at Neurocrine Biosciences, Inc. from 1998 to 2008.
During his tenure, he held the title of Senior Director & Head-Endocrinology & Metabolism.
In terms of education, Dr. Struthers attended the University of California San Diego, where he obtained undergraduate and doctorate degrees.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-04-17 | 1,159,290 ( 1.49% ) | 54 M $ | 2024-03-30 |
Scott Struthers active positions
| Companies | Position | Start |
|---|---|---|
| CRINETICS PHARMACEUTICALS, INC. | Founder | 2007-12-31 |
| The San Diego Entrepreneurs Exchange | Founder | 2008-12-31 |
Radionetics Oncology, Inc.
 Radionetics Oncology, Inc. Pharmaceuticals: MajorHealth Technology Radionetics Oncology, Inc. is a clinical stage radiopharmaceutical company based in Menlo Park, CA. Radionetics Oncology, Inc. focuses on the discovery and development of novel radiotherapeutics for the treatment of various oncology indications. Radionetics Oncology spun out of Crinetics Pharmaceuticals and is supported by Frazier Life Sciences, 5AM Ventures, DCVC Bio, Crinetics Pharmaceuticals, and GordonMD Investments. The company is advancing a pipeline of small molecule radioligands that target G-protein coupled receptors to treat a wide range of cancers, including adrenocortical carcinoma, breast cancer, and lung cancer. The company's platform technology uses nonpeptide, small molecule targeting to deliver therapeutic radioisotopes selectively to tumors expressing peptide receptors. The company's pipeline consists of multiple lead drug candidates, and they are conducting additional drug discovery efforts in collaboration with Crinetics Pharmaceuticals. The market for radiopharmaceuticals is expected to rise to $12.6 billion by 2027. The company was founded by Scott R. Struthers, and Paul A. Grayson has been the CEO since 2024. | Founder | 2021-09-30 |
Former positions of Scott Struthers
| Companies | Position | End |
|---|---|---|
| NEUROCRINE BIOSCIENCES, INC. | Director/Board Member | 2007-12-31 |
ScienceMedia, Inc.
 ScienceMedia, Inc. Electronics DistributorsDistribution Services ScienceMedia, Inc. provides marketing, communication, and e-learning solutions for life sciences and higher education markets. It offers solutions through the Web site and intranet, as well as through CD-ROMs. The company was founded by Arnold T. Hagler in 1995 and is headquartered in San Diego, CA. | Founder | 1997-12-31 |
Training of Scott Struthers
| University of California San Diego | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| NEUROCRINE BIOSCIENCES, INC. | Health Technology |
| CRINETICS PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 3 |
|---|---|
ScienceMedia, Inc.
ScienceMedia, Inc. Electronics DistributorsDistribution Services ScienceMedia, Inc. provides marketing, communication, and e-learning solutions for life sciences and higher education markets. It offers solutions through the Web site and intranet, as well as through CD-ROMs. The company was founded by Arnold T. Hagler in 1995 and is headquartered in San Diego, CA. | Distribution Services |
| The San Diego Entrepreneurs Exchange | |
Radionetics Oncology, Inc.
Radionetics Oncology, Inc. Pharmaceuticals: MajorHealth Technology Radionetics Oncology, Inc. is a clinical stage radiopharmaceutical company based in Menlo Park, CA. Radionetics Oncology, Inc. focuses on the discovery and development of novel radiotherapeutics for the treatment of various oncology indications. Radionetics Oncology spun out of Crinetics Pharmaceuticals and is supported by Frazier Life Sciences, 5AM Ventures, DCVC Bio, Crinetics Pharmaceuticals, and GordonMD Investments. The company is advancing a pipeline of small molecule radioligands that target G-protein coupled receptors to treat a wide range of cancers, including adrenocortical carcinoma, breast cancer, and lung cancer. The company's platform technology uses nonpeptide, small molecule targeting to deliver therapeutic radioisotopes selectively to tumors expressing peptide receptors. The company's pipeline consists of multiple lead drug candidates, and they are conducting additional drug discovery efforts in collaboration with Crinetics Pharmaceuticals. The market for radiopharmaceuticals is expected to rise to $12.6 billion by 2027. The company was founded by Scott R. Struthers, and Paul A. Grayson has been the CEO since 2024. | Health Technology |
- Stock Market
- Insiders
- Scott Struthers
